Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Whitehawk Therapeutics IncNASDAQ: WHWK

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $7.15M a year earlier. Trailing-twelve-month revenue was $0. Over 3 fiscal years it compounded at -22.3% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of $8.83M (+23.6%) for the fiscal year ending Dec 2026, a step up from the -72.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$7.15M-72.5% YoY
LTMMar 2026
$0-100.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-72.5%+23.6%+96.1 pp
3-year CAGR-22.3%+23.6%+45.8 pp
5-year CAGR+36.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
7.15M USD
Year-over-year change
-72.5%
4-year CAGR
+58.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -100.0% is the 4th highest of 5, against a peer median of -29.3%.
  • Over three fiscal years its annual growth of -22.3% compares with a peer median of -0.1%.
WHWK Competitors
Revenue for WHWK and competitors
Company Period LTM YoY 3-year CAGR
MGNXMacroGenics, Inc.LTM Mar 2026$157.08M USD+3.1%-0.1%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.12M USD+1199.6%+69.0%
CLNNClene Inc.LTM Mar 2026$134K USD-61.7%-24.9%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$0 USD-100.0%-22.3%
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 USD——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$0 CAD——
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD——
Peer median (excluding WHWK) —-29.3%-0.1%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12M15.22M24.35M25.98M7.15M
Cost of Revenue19.67M34M51.74M54.05M760K
Gross Profit(18.55M)(18.78M)(27.38M)(28.07M)6.39M
Gross Margin-1656.3%-123.4%-112.4%-108.0%89.4%
Research & Development19.67M32.66M48.93M51.03M90.96M
Selling, General & Admin18.51M40.18M44.55M36.75M29.82M
Operating Expenses92.67M43.9M44.55M39.39M120.79M
Depreciation & Amortization105K159K169K193K79K
EBITDA(36.96M)(58.8M)(65.37M)(64.63M)(20.52M)
EBITDA Margin-3299.6%-386.4%-268.4%-248.7%-287.2%
Operating Income(111.22M)(62.68M)(71.93M)(67.46M)(114.4M)
Operating Margin-9930.1%-411.9%-295.4%-259.6%-1601.1%
Interest Income13K2.4M6.4M3.93M6.23M
Interest Expense665K230K231K154K0
Other Income / Expenses1.13M2.17M6.17M3.77M93.8M
Income Before Tax(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Pre-Tax Margin-9829.3%-397.7%-270.0%-245.1%-288.3%
Income Tax Expense2K0000
Net Income(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Net Margin-9829.5%-397.7%-270.0%-245.1%-288.3%
EPS (Basic)(12.41)(2.69)(2.44)(2.36)(0.33)
EPS (Diluted)(12.41)(2.69)(2.44)(2.36)(0.33)
Weighted Avg Shares8.87M22.51M26.92M27.03M61.89M
Weighted Avg Shares (Diluted)8.92M22.51M26.92M27.03M61.89M

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.